RxDoctor Payments Data

Wafa Elhassan, MD

Internal Medicine · Dearborn, MINPI 1699115535

Payments from drug & device makers

$380in general payments, 2019–2025

Across 16 payments — averaging $23.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$106
  • Mylan Specialty L.p.$70
  • AstraZeneca$57
  • Pfizer$23
  • Novo Nordisk$22
  • Xeris Pharmaceuticals, Inc.$22
  • plus $80 from 5 others

What the payments were for

  • Food & beverage$380100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$380 in reported general payments places this provider in the 60th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$200,107
Medicare patients
354
Services billed
2,128

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban69$40,984
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate14$35,270
JardianceEmpagliflozin32$21,110
EntrestoSacubitril/Valsartan31$18,885
OzempicSemaglutide13$12,778
MyrbetriqMirabegron27$11,788
Breo ElliptaFluticasone/Vilanterol26$10,940
TrulicityDulaglutide11$10,924
FarxigaDapagliflozin Propanediol18$10,282
XareltoRivaroxaban12$6,987
Atorvastatin Calcium523$6,053
Incruse ElliptaUmeclidinium Bromide14$5,139
Fluticasone-SalmeterolFluticasone Propion/Salmeterol32$4,200
Albuterol Sulfate HfaAlbuterol Sulfate88$3,766
Lantus SolostarInsulin Glargine,hum.Rec.Anlog34$3,243

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$23$40,98469 claims
Novo NordiskOzempic$22$12,77813 claims
Lilly USA, LLCTrulicity$106$10,92411 claims
AstraZenecaFarxiga$57$10,28218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Dearborn

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →